United Kingdom Cell & Gene Therapy Cold Chain Logistics Market By Component (Cryogenic Shippers, Cryogenic Storage Freezers, Ultra Low Freezers, Cold Chain Management Systems, Shipment and Storage Medium, Cryogenic Packout Kits Others {Shipment Containers, Reusable Boxes, etc.}), By Services Offered (Transportation, Storage, Packaging), By Mode of Transportation (Air, Ground, Water), By Holding Te
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationUnited Kingdom Cell & Gene Therapy Cold Chain Logistics Market By Component (Cryogenic Shippers, Cryogenic Storage Freezers, Ultra Low Freezers, Cold Chain Management Systems, Shipment and Storage Medium, Cryogenic Packout Kits Others {Shipment Containers, Reusable Boxes, etc.}), By Services Offered (Transportation, Storage, Packaging), By Mode of Transportation (Air, Ground, Water), By Holding Te
United Kingdom Cell & Gene Therapy Cold Chain Logistics market is anticipated to grow significantly rate in the projected period of 2028 due to increasing demand for cell and gene therapies, development of advanced cold chain technologies and solutions, supportive regulatory environment & government initiatives, and presence of a strong research and innovation ecosystem.
As of 6th May 2023 there are around 23,372 clinical trials in different phases of development across the United Kingdom.
In 2021, the United Kingdom government also announced a USD 11 million investment to establish a new Cell and Gene Therapy Catapult Innovation Centre in Stevenage
Development of Advanced Cold Chain Technologies and Solutions is a Factor that Driving the Market Growth
According to clinicaltrials.gov, there are around 610 studies in different phases of development related to cell therapies in the United Kingdom.
The logistics associated with cell therapies are complex and require specialized infrastructure to ensure their safe and efficient transportation. Cold chain logistics is essential for maintaining the viability and potency of these therapies during transportation. This process involves maintaining a specific temperature range throughout the entire supply chain, from production to delivery.
The continuous investment in the gene and therapy sector by United Kingdom government can increase its uneven share of the global gene and therapy market to 15% which equates to more than USD 11 billion of revenue (predominately exports) and 18,000 jobs in 2035.
The investment in the United Kingdom cell and gene therapy sector is expected to drive growth in the associated logistics services, including cold chain logistics. As more cell therapies are developed and approved for commercial use, the demand for specialized logistics services will continue to grow. In addition to the growth of the cell and gene therapy sector, the COVID-19 pandemic has also contributed to the increased demand for cold chain logistics services. The pandemic has highlighted the importance of safe and efficient vaccine distribution, which requires specialized logistics services to maintain the integrity of the vaccines during transportation. Thus, all the above-mentioned advancement is expected to drive the growth of the United Kingdom cell & gene therapy cold chain logistics market.
Supportive Regulatory Environment and Government Initiatives is Pushing Cell & Gene Therapy Cold Chain Logistics Market Growth
United Kingdom cell and gene therapy cold chain logistics market is expected to see significant growth in the coming years, on account of the supportive regulatory environment and government initiatives. The United Kingdom has established itself as a global leader in cell and gene therapy research and development, and the government has taken several steps to support the growth of this sector, including initiatives to promote innovation and investment in industry. The United Kingdom has a robust regulatory framework in place that provides a clear path to market for these therapies. The Medicines and Healthcare Products Regulatory Agency (MHRA) is responsible for regulating cell and gene therapies in the United Kingdom, and it has established a dedicated team to support the development and approval of these therapies.
The MHRA has also launched several initiatives to promote the development of cell and gene therapies in the United Kingdom. For instance, United Kingdom has established the Accelerated Access Pathway (AAP), which provides a streamlined regulatory process for innovative therapies that address unmet medical needs. This initiative helps to speed up the development and approval process for cell and gene therapies, enabling them to reach patients more quickly.
. In 2018, the government announced the Life Sciences Sector Deal, which included a USD 1.46 billion investment in the sector. This investment is intended to support the development of innovative therapies and technologies, including cell and gene therapies, genomics, and AI-powered diagnosis.
The government has also established the Cell and Gene Therapy Catapult, a center of excellence for the development and commercialization of cell and gene therapies. Catapult provides state-of-the-art facilities and expertise to support the development of these therapies and has helped to position the United Kingdom as a global leader in the industry.
The supportive regulatory environment and government initiatives are expected to propel the growth of the United Kingdom's cell and gene therapy cold chain logistics market. The logistics associated with these therapies are complex and require specialized infrastructure to ensure their safe and efficient transportation. Cold chain logistics is essential for maintaining the viability and potency of these therapies during transportation. As the United Kingdom cell and gene therapy cold chain logistics market are supported by several companies that specialize in providing these services. These companies offer a range of services, including temperature-controlled packaging, transport, storage, and monitoring. They use advanced technologies to ensure that the cell therapies remain at the required temperature throughout the entire supply chain.
Technological Advancements are Key Reason that Responsible for Market Growth
United Kingdom cell and gene therapy cold chain logistics market is continuously evolving due to technological advancements that are transforming the industry. With the increasing demand for cell and gene therapies, it is essential to have efficient and safe logistics processes to transport these therapies. The use of advanced technologies has become a significant trend in the industry, allowing for the optimization of logistics processes and the reduction of risks associated with transportation.
automation and robotics in logistics processes
The adoption of real-time monitoring and tracking technologies is major trend in the United Kingdom's cell and gene therapy cold chain logistics market. The use of temperature sensors and other monitoring devices enables logistics providers to track the location and temperature of cell and gene therapies throughout the transportation process. The technology helps to ensure that the therapies are transported within the required temperature range, and in case of any deviations, the logistics providers can take corrective actions quickly.
cloud-based logistics management systems
blockchain technology
artificial intelligence (AI) and machine learning (ML)
Market Segmentation
United Kingdom Cell & Gene Therapy Cold Chain Logistics market
Company Profiles
Atelerix Ltd., Life Science Group Ltd (LSG), Arvato Group, DGP Intelius Ltd., QuickSTAT (A Kuehne + Nagel Company), BIOCAIR, TrakCel, Cryoport UK Limited, Patheon UK Limited (Thermo Fischer Scientific UK), Catalent UK are some of the key players of United Kingdom cell & gene therapy cold chain logistics market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, Volume in tons and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, volume forecasting, Company shares, competitive landscape, growth factors, and trends |
| Segments covered | Component Services Offered Mode of Transportation Holding Temperature Range End User |
| Country scope | Scotland, South-East, London, South-West, East-Anglia, Yorkshire & Humberside, and East Midlands |
| Key companies profiled | Atelerix Ltd., Life Science Group Ltd (LSG), Arvato Group, DGP Intelius Ltd., QuickSTAT (A Kuehne + Nagel Company), BIOCAIR, TrakCel, Cryoport UK Limited, Patheon UK Limited (Thermo Fischer Scientific UK), Catalent UK |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy